Nephrologisches Zentrum Villingen-Schwenningen GbR — Clinical Trial Site

8 Registered trials

3 Currently recruiting

Organisation

Nephrologisches Zentrum Villingen-Schwenningen GbR

Location

Villingen-Schwenningen, Germany

Identifier

ORG-100045968

Address

Albert-Schweitzer-Strasse 6, Schilterhaeusle, 78052, Germany

Departments

N/A
na
Nephrologisches Zentrum Villingen-Schwenningen
Nephrology

Clinical trials at this site (8)

Search interface

ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting

2024-519345-30-00 IgA nephropathy 5 2025-11-12
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr… Ended

2022-502102-32-00 Primary Immunoglobulin A (IgA) Nephropathy 5 2023-11-16
Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended

2023-504597-37-00 Focal segmental glomerulosclerosis 5 2022-03-25
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of … Ended

2024-513227-16-00 Immunoglobulin A Nephropathy (IgAN) 5 2021-05-19
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Focal segmental glomerulosclerosis (FSGS) 5 2018-10-15